EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment

Cancer Biology and Therapy

Volumn 17, Issue 3, 2016, Pages 320-327

  Que, Dan ^a   Xiao, He ^a   Zhao, Baojian ^b   Zhang, Xu ^b   Wang, Qiushi ^a   Xiao, Hualiang ^a   Wang, Ge ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b Phoenix Biotech (Beijing) Co Ltd   (China)

Author keywords

CEA; DHPLC; EGFR mutation; EGFR TKI; NSCLC; survival; treatment response

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; ICOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR MARKER; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ARTICLE; BLOOD SAMPLING; CANCER SURVIVAL; CANCER TISSUE; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DISEASE MARKER; EXON; FEASIBILITY STUDY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTANT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MUTATION; PREDICTIVE VALUE; RETROSPECTIVE STUDY;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 84961204150     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2016.1139238     Document Type: Article

References (35)

1. W.D.Travis, E.Brambilla, G.J.Riely. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 2013; 31:992–1001; PMID:23401443; http://dx.doi.org/10.1200/JCO.2012.46.9270
2. R.Govindan, N.Page, D.Morgensztern, W.Read, R.Tierney, A.Vlahiotis, E.L.Spitznagel, J.Piccirillo. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24:4539–44; PMID:17008692; http://dx.doi.org/10.1200/JCO.2005.04.4859
3. X.Zhao, R.B.Han, J.Zhao, J.Wang, F.Yang, W.Zhong, L.Zhang, L.Y.Li, M.Z.Wang. Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients. Respiration 2013; 85:119–25; PMID:22797485; http://dx.doi.org/10.1159/000338790
4. T.Mitsudomi, S.Morita, Y.Yatabe, S.Negoro, I.Okamoto, J.Tsurutani, T.Seto, M.Satouchi, H.Tada, T.Hirashima, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11:121–8; PMID:20022809; http://dx.doi.org/10.1016/S1470-2045(09)70364-X
5. Y.L.Wu, C.Zhou, C.P.Hu, J.Feng, S.Lu, Y.Huang, W.Li, M.Hou, J.H.Shi, K.Y.Lee, et al. Lancet Oncol 2014; 15:213–22; PMID:24439929; http://dx.doi.org/10.1016/S1470-2045(13)70604-1
6. J.Y.Douillard, F.A.Shepherd, V.Hirsh, T.Mok, M.A.Socinski, R.Gervais, M.L.Liao, H.Bischoff, M.Reck, M.V.Sellers, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010; 28:744–52; PMID:20038723; http://dx.doi.org/10.1200/JCO.2009.24.3030
7. T.S.Mok, Y.L.Wu, S.Thongprasert, C.H.Yang, D.T.Chu, N.Saijo, P.Sunpaweravong, B.Han, B.Margono, Y.Ichinose, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947–57; PMID:19692680; http://dx.doi.org/10.1056/NEJMoa0810699
8. R.Rosell, E.Carcereny, R.Gervais, A.Vergnenegre, B.Massuti, E.Felip, R.Palmero, R.Garcia-Gomez, C.Pallares, J.M.Sanchez, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13:239–46; PMID:22285168; http://dx.doi.org/10.1016/S1470-2045(11)70393-X
9. M.J.Overman, J.Modak, S.Kopetz, R.Murthy, J.C.Yao, M.E.Hicks, J.L.Abbruzzese, A.L.Tam. Use of research biopsies in clinical trials: Are risks and benefits adequately discussed?. J Clin Oncol 2013; 31:17–22; PMID:23129736; http://dx.doi.org/10.1200/JCO.2012.43.1718
10. K.Taniguchi, J.Uchida, K.Nishino, T.Kumagai, T.Okuyama, J.Okami, M.Higashiyama, K.Kodama, F.Imamura, K.Kato. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 2011; 17:7808–15; PMID:21976538; http://dx.doi.org/10.1158/1078-0432.CCR-11-1712
11. K.Goto, Y.Ichinose, Y.Ohe, N.Yamamoto, S.Negoro, K.Nishio, Y.Itoh, H.Jiang, E.Duffield, R.McCormack, et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 2012; 7:115–21; PMID:21900837; http://dx.doi.org/10.1097/JTO.0b013e3182307f98
12. G.Zhu, X.Ye, Z.Dong, Y.C.Lu, Y.Sun, Y.Liu, R.McCormack, Y.Gu, X.Liu. Highly sensitive droplet digital PCR method for detection of EGFR-activating mutations in plasma cell-free DNA from patients with advanced non-small cell lung cancer. J Mol Diagn 2015; 17:265–72; PMID:25769900; http://dx.doi.org/10.1016/j.jmoldx.2015.01.004
13. G.R.Oxnard, C.P.Paweletz, Y.Kuang, S.L.Mach, A.O'Connell, M.M.Messineo, J.J.Luke, M.Butaney, P.Kirschmeier, D.M.Jackman, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014; 20:1698–705; PMID:24429876; http://dx.doi.org/10.1158/1078-0432.CCR-13-2482
14. H.Bai, L.Mao, H.S.Wang, J.Zhao, L.Yang, T.T.An, X.Wang, C.J.Duan, N.M.Wu, Z.Q.Guo, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009; 27:2653–9; PMID:19414683; http://dx.doi.org/10.1200/JCO.2008.17.3930
15. C.H.Chiu, Y.N.Shih, C.M.Tsai, J.L.Liou, Y.M.Chen, R.P.Perng. Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib. Lung Cancer 2007; 57:213–21; PMID:17449138; http://dx.doi.org/10.1016/j.lungcan.2007.02.016
16. O.Fiala, M.Pesek, J.Finek, L.Benesova, M.Minarik, Z.Bortlicek, O.Topolcan. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib. Anticancer Res 2014; 34:3205–10; PMID:24922695.
17. M.Jung, S.H.Kim, Y.J.Lee, S.Hong, Y.A.Kang, S.K.Kim, J.Chang, S.Y.Rha, J.H.Kim, D.J.Kim, et al. Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Exp Ther Med 2011; 2:685–93; PMID:22977560; http://dx.doi.org/10.3892/etm.2011.273
18. E.A.Eisenhauer, P.Therasse, J.Bogaerts, L.H.Schwartz, D.Sargent, R.Ford, J.Dancey, S.Arbuck, S.Gwyther, M.Mooney, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228–47; PMID:19097774; http://dx.doi.org/10.1016/j.ejca.2008.10.026
19. X.Li, R.Ren, S.Ren, X.Chen, W.Cai, F.Zhou, Y.Zhang, C.Su, C.Zhao, J.Li, et al. Peripheral blood for epidermal growth factor receptor mutation detection in non-small cell lung cancer patients. Transl Oncol 2014; 7:341–8; PMID:25180058; http://dx.doi.org/10.1016/j.tranon.2014.04.006
20. H.Kimura, M.Suminoe, K.Kasahara, T.Sone, T.Araya, S.Tamori, F.Koizumi, K.Nishio, K.Miyamoto, M.Fujimura, et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 2007; 97:778–84; PMID:17848912; http://dx.doi.org/10.1038/sj.bjc.6603949
21. Z.Huang, Z.J.Wang, H.Bai, M.N.Wu, T.T.An, J.Zhao, L.Yang, J.C.Duan, M.L.Zhuo, Y.Y.Wang, et al. The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. Thoracic Cancer 2012; 3:334–40; http://dx.doi.org/10.1111/j.1759-7714.2012.00133.x
22. Z.Yang, M.J.Long, F.Wang, Q.Chen, B.J.Zhao, Y.Guo, Y.Huang, X.L.Su, X.Zhang, W.Cui. Detection and clinical significance of EGFR and KRAS mutation in peripheral blood from tumor patients by REDE-DHPLC. Chin J Lab Med, 2011; 34:327–32. (in Chinese); http://dx.doi.org/10.3760/cma.j.issn.1009-9158.2011.04.008
23. C.Bettegowda, M.Sausen, R.J.Leary, I.Kinde, Y.Wang, N.Agrawal, B.R.Bartlett, H.Wang, B.Luber, R.M.Alani, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014; 6:224ra24; http://dx.doi.org/10.1126/scitranslmed.3007094
24. J.Zhang, J.Fujimoto, J.Zhang, D.C.Wedge, X.Song, J.Zhang, S.Seth, C.W.Chow, Y.Cao, C.Gumbs, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014, 346:256–9; http://dx.doi.org/10.1126/science.1256930
25. C.Swanton. Intratumor heterogeneity: evolution through space and time. Cancer Res 2012; 72:4875–82; PMID:23002210; http://dx.doi.org/10.1158/0008-5472.CAN-12-2217
26. E.C.de Bruin, N.McGranahan, R.Mitter, M.Salm, D.C.Wedge, L.Yates, M.Jamal-Hanjani, S.Shafi, N.Murugaesu, A.J.Rowan, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014; 346:251–6; PMID:25301630; http://dx.doi.org/10.1126/science.1253462
27. Y.Zhang, B.Jin, M.Shao, Y.Dong, Y.Lou, A.Huang, B.Han. Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma. Tumour Biol 2014; 35:4921–8; PMID:24459065; http://dx.doi.org/10.1007/s13277-014-1646-1
28. F.Shoji, I.Yoshino, T.Yano, T.Kometani, T.Ohba, H.Kouso, T.Takenaka, N.Miura, H.Okazaki, Y.Maehara. Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. Cancer 2007; 110:2793–8; PMID:17941001; http://dx.doi.org/10.1002/cncr.23101
29. M.Okada, W.Nishio, T.Sakamoto, K.Uchino, T.Yuki, A.Nakagawa, N.Tsubota. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease. Ann Thorac Surg 2004; 78:216–21; PMID:15223432; http://dx.doi.org/10.1016/j.athoracsur.2004.02.009
30. A.Ardizzoni, M.A.Cafferata, M.Tiseo, R.Filiberti, P.Marroni, F.Grossi, M.Paganuzzi. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer. Cancer 2006; 107:2842–9; PMID:17103443; http://dx.doi.org/10.1002/cncr.22330
31. T.Okamoto, T.Nakamura, J.Ikeda, R.Maruyama, F.Shoji, T.Miyake, H.Wataya, Y.Ichinose. Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer. Eur J Cancer 2005; 41:1286–90; PMID:15939264; http://dx.doi.org/10.1016/j.ejca.2005.03.011
32. O.Arrieta, D.Saavedra-Perez, R.Kuri, A.Aviles-Salas, L.Martinez, D.Mendoza-Posada, P.Castillo, A.Astorga, E.Guzman, J.De la Garza. Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis. BMC Cancer 2009; 9:119; PMID:19386089; http://dx.doi.org/10.1186/1471-2407-9-119
33. R.Sordella, D.W.Bell, D.A.Haber, J.Settleman. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305:1163–7; PMID:15284455; http://dx.doi.org/10.1126/science.1101637
34. J.S.Tseng, T.Y.Yang, C.R.Tsai, K.C.Chen, K.H.Hsu, M.H.Tsai, S.L.Yu, K.Y.Su, J.J.Chen, G.C.Chang. Dynamic Plasma EGFR Mutation Status as a Predictor of EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Adenocarcinoma. J Thorac Oncol 2015; 10: 603–10; PMID:25514801; http://dx.doi.org/10.1097/JTO.0000000000000443
35. T.Mok, Y.L.Wu, J.S.Lee, C.J.Yu, V.Sriuranpong, J.Sandoval-Tan, G.Ladrera, S.Thongprasert, V.Srimuninnimit, M.Liao, et al. Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Clin Cancer Res 2015; 21: 3196–203; PMID:25829397; http://dx.doi.org/10.1158/1078-0432.CCR-14-2594